Treatment with alemtuzumab induces depletion and reconstitution of circulating CD52+ B and T lymphocytes, resulting in sustained changes of the adaptive immunity, which is thought to contribute to the clinical benefits in autoimmune disorders [123]. This evidence concerns the gene CD52 and autoimmune disease.